The global Artificial Heart market, valued at USD 2.10 Billion in 2025, is projected to reach USD 5.80 Billion by 2035, registering a revenue CAGR of 10.7% during the forecast period. Market growth is being supported by the increasing prevalence of end-stage heart failure and the persistent shortage of donor hearts available for transplantation. According to the World Health Organization (WHO), cardiovascular diseases remain the leading cause of death globally, accounting for nearly 18 million deaths each year. Growing demand for advanced mechanical circulatory support devices, combined with continued improvements in cardiac surgery and critical care infrastructure, is increasing the adoption of artificial heart systems in specialized healthcare facilities.

Request a Sample Report with Table of Contents and Figures to click Here: @ https://www.emergenresearch.com/request-sample/10695

Advances in biomaterials, miniaturized electronic control systems, and long-term circulatory support technologies continue to improve the clinical performance of artificial heart devices. Healthcare providers are increasingly using artificial hearts and ventricular assist devices as bridge-to-transplant and destination therapy options for patients who are not eligible for immediate transplantation. Regulatory support for innovative cardiovascular technologies and growing investment in cardiac care programs are also contributing to market expansion. For instance, in September 2024, BiVACOR, Australia, announced the first successful implantation of its Total Artificial Heart under the U.S. Food and Drug Administration's Early Feasibility Study, marking an important clinical milestone in artificial heart development. Continued clinical research, hospital adoption, and product innovation are supporting commercial opportunities across the sector. These are some of the key factors driving revenue growth of the Artificial Heart market.

However, artificial heart systems remain among the most expensive implantable cardiovascular devices, limiting adoption in cost-sensitive healthcare markets. Clinical implantation procedures require highly specialized surgical teams and advanced hospital infrastructure, restricting availability to selected cardiac centers. Regulatory approval processes remain extensive because of long-term safety, reliability, and post-market surveillance requirements. Risks associated with infection, thrombosis, and device-related complications also continue to influence clinical decision-making. These factors are expected to limit Artificial Heart market growth to some extent over the forecast period.

The total artificial heart segment accounted for the largest share of market revenue in 2025. These devices provide complete replacement of the native heart in patients with severe biventricular heart failure when conventional treatment options are no longer effective. Increasing use in bridge-to-transplant procedures and continued technological improvements are supporting demand within specialized cardiac centers.

To Read More About The Report, Visit @ https://www.emergenresearch.com/industry-report/artificial-heart-market

The portable and next-generation artificial heart systems segment is expected to register the fastest growth during the forecast period. Manufacturers are focusing on compact power systems, improved battery life, wireless monitoring, and enhanced biocompatibility to improve patient mobility and long-term outcomes. Growing clinical experience and ongoing research programs are expected to expand adoption of these advanced systems.

North America accounted for the largest share of the global Artificial Heart market in 2025. The region benefits from advanced cardiac care infrastructure, favorable reimbursement for selected therapies, and high levels of research investment. The United States continues to lead clinical adoption through major transplant centers and medical device manufacturers. Companies including SynCardia Systems and Abiomed, a Johnson & Johnson MedTech company, continue to invest in mechanical circulatory support technologies, while the U.S. Food and Drug Administration (FDA) supports clinical evaluation of next-generation artificial heart devices through investigational programs.

Europe held a considerable share of the market due to established cardiovascular treatment networks and strong public healthcare systems. Countries including Germany, France, Italy, and the United Kingdom continue to expand access to advanced heart failure treatment through specialized cardiac centers. Companies such as CARMAT, France, continue to advance total artificial heart technologies through ongoing clinical and commercial activities, supported by regulatory pathways within the European healthcare system.

Requesting A Customised Report @ https://www.emergenresearch.com/request-for-customization/10695

Asia Pacific is expected to register the fastest market growth during the forecast period. Rising cardiovascular disease prevalence, increasing healthcare expenditure, and expanding cardiac surgery capabilities are contributing to regional demand. Governments across China, Japan, South Korea, and India continue to invest in tertiary healthcare infrastructure and advanced cardiac treatment programs. Japan remains an important market because of its aging population and established expertise in cardiovascular care, while regional hospitals continue to increase participation in mechanical circulatory support research and clinical adoption.

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Media Contact

Contact us:
14671 110 Avenue, Surrey, British Columbia, V3R2A9

Eric Lee
Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +12092086299

E-mail: [email protected]

Visit for More Insights: https://www.emergenresearch.com/insights